LOGO
LOGO

FDA Calendar - Rhythm Pharmaceuticals, Inc.

Company Name Rhythm Pharmaceuticals, Inc.
RYTM
Drug Name IMCIVREE (sNDA)
Event Name FDA decision on expanded use of IMCIVREE for the treatment of acquired hypothalamic obesity
Event Date 03/20/2026
Outcome Date 03/19/2026
Outcome FDA approved the expanded use of IMCIVREE for the treatment of acquired hypothalamic obesity on March 19, 2026
Drug Status
Rival Drugs
Market Potential
Other Approvals Imcivree is already approved in the U.S. for chronic weight management in patients with obesity due to Bardet-Biedl syndrome, POMC, PCSK1 or LEPR Deficiency
News
Rhythm Secures FDA Approval For IMCIVREE In Acquired Hypothalamic Obesity
Return to FDA Calendar
Editors Pick
aerospace 21042026 lt

GE Aerospace Q1 Adj. Profit Rises; Backs FY26 Outlook

April 21, 2026 09:43 ET
pepsi 21042026 lt

PepsiCo Q1 Net Profit, Revenues Rise

April 16, 2026 07:59 ET
morganstanley 15042026 lt

Morgan Stanley Q1 Net Profit Rises 30%

April 15, 2026 08:55 ET
goldmansachsco 13042026 lt

Goldman Sachs Q1 Profit Climbs On Revenue Strength; But Stock Down

April 13, 2026 08:24 ET
Copyright © 2026 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us   |   Contact Us   |   Privacy   |   Sitemap